Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Will Spend $600 Mil. On Cell Culture-Derived Influenza Vaccine Facility

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss company to start construction on the first such manufacturing plant in the U.S. in 2007.

You may also be interested in...



HHS Contracts Aim To Fund Adjuvant Vaccines Research

GSK, Novartis and Iomai are awarded multi-million dollar contracts to fund adjuvant-based pandemic influenza vaccine development.

HHS Contracts Aim To Fund Adjuvant Vaccines Research

GSK, Novartis and Iomai are awarded multi-million dollar contracts to fund adjuvant-based pandemic influenza vaccine development.

Novartis Global Vaccines Business To Be Headquartered In The U.S.

The Swiss drug maker says its new headquarters in Cambridge, Mass. should be fully staffed in the second quarter of 2007.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel